CHEK
Price
$3.11
Change
+$0.36 (+13.09%)
Updated
Mar 28, 6:59 PM EST
6 days until earnings call
QTRX
Price
$23.56
Change
+$0.63 (+2.75%)
Updated
Mar 28, 6:59 PM EST
39 days until earnings call
Ad is loading...

Compare trend and price CHEK vs QTRX

Header iconCHEK vs QTRX Comparison
Open Charts CHEK vs QTRXBanner chart's image
Check-Cap
Price$3.11
Change+$0.36 (+13.09%)
Volume$247.22K
CapitalizationN/A
Quanterix
Price$23.56
Change+$0.63 (+2.75%)
Volume$237.78K
CapitalizationN/A
View a ticker or compare two or three
CHEK vs QTRX Comparison Chart

Loading...

CHEKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
QTRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CHEK vs. QTRX commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHEK is a Hold and QTRX is a Hold.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (CHEK: $3.00 vs. QTRX: $23.59)
Brand notoriety: CHEK and QTRX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CHEK: 134% vs. QTRX: 90%
Market capitalization -- CHEK: $17.55M vs. QTRX: $898.11M
CHEK [@Medical Specialties] is valued at $17.55M. QTRX’s [@Medical Specialties] market capitalization is $898.11M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHEK’s FA Score shows that 1 FA rating(s) are green whileQTRX’s FA Score has 0 green FA rating(s).

  • CHEK’s FA Score: 1 green, 4 red.
  • QTRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CHEK and QTRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHEK’s TA Score shows that 6 TA indicator(s) are bullish while QTRX’s TA Score has 5 bullish TA indicator(s).

  • CHEK’s TA Score: 6 bullish, 4 bearish.
  • QTRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CHEK is a better buy in the short-term than QTRX.

Price Growth

CHEK (@Medical Specialties) experienced а +49.25% price change this week, while QTRX (@Medical Specialties) price change was -2.58% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.84%. For the same industry, the average monthly price growth was -0.26%, and the average quarterly price growth was +4.27%.

Reported Earning Dates

CHEK is expected to report earnings on May 15, 2024.

QTRX is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Medical Specialties (+0.84% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for CHEK with price predictions.
OPEN
A.I.dvisor published
a Summary for QTRX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
QTRX($898M) has a higher market cap than CHEK($17.6M). CHEK YTD gains are higher at: 44.231 vs. QTRX (-13.698). CHEK has higher annual earnings (EBITDA): -18.8M vs. QTRX (-39.79M). QTRX has more cash in the bank: 321M vs. CHEK (32.1M). CHEK has less debt than QTRX: CHEK (83K) vs QTRX (41.5M). QTRX has higher revenues than CHEK: QTRX (121M) vs CHEK (0).
CHEKQTRXCHEK / QTRX
Capitalization17.6M898M2%
EBITDA-18.8M-39.79M47%
Gain YTD44.231-13.698-323%
P/E RatioN/AN/A-
Revenue0121M-
Total Cash32.1M321M10%
Total Debt83K41.5M0%
FUNDAMENTALS RATINGS
CHEK vs QTRX: Fundamental Ratings
CHEK
QTRX
OUTLOOK RATING
1..100
3776
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
3749
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHEK's Valuation (29) in the Medical Specialties industry is in the same range as QTRX (40) in the Pharmaceuticals Major industry. This means that CHEK’s stock grew similarly to QTRX’s over the last 12 months.

CHEK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as QTRX (100) in the Pharmaceuticals Major industry. This means that CHEK’s stock grew similarly to QTRX’s over the last 12 months.

QTRX's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as CHEK (97) in the Medical Specialties industry. This means that QTRX’s stock grew similarly to CHEK’s over the last 12 months.

CHEK's Price Growth Rating (37) in the Medical Specialties industry is in the same range as QTRX (49) in the Pharmaceuticals Major industry. This means that CHEK’s stock grew similarly to QTRX’s over the last 12 months.

CHEK's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as QTRX (100) in the Pharmaceuticals Major industry. This means that CHEK’s stock grew similarly to QTRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHEKQTRX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
CHEKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
QTRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OISGX13.62N/A
N/A
Optimum Small-Mid Cap Growth Instl
MIGNX44.39N/A
N/A
MFS Massachusetts Inv Gr Stk R6
GOFIX21.85N/A
N/A
GMO Resources III
PGLOX16.69-0.01
-0.06%
T. Rowe Price Global Consumer
CGCIX12.58-0.01
-0.08%
Calamos Global Opportunities I

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and TWST have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and TWST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
+9.09%
TWST - CHEK
26%
Poorly correlated
-0.49%
RSLS - CHEK
26%
Poorly correlated
+0.99%
WRBY - CHEK
25%
Poorly correlated
+2.72%
SENS - CHEK
25%
Poorly correlated
-5.77%
MYGN - CHEK
23%
Poorly correlated
-0.37%
More

QTRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, QTRX has been loosely correlated with CDNA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if QTRX jumps, then CDNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QTRX
1D Price
Change %
QTRX100%
+2.90%
CDNA - QTRX
45%
Loosely correlated
+0.57%
MASS - QTRX
45%
Loosely correlated
+8.63%
VREX - QTRX
42%
Loosely correlated
+2.55%
CERS - QTRX
41%
Loosely correlated
+5.59%
ATRC - QTRX
41%
Loosely correlated
+0.90%
More